The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer (Q80155214)

From Wikidata

Jump to navigation Jump to search

scientific article published on 11 December 2007

Language	Label	Description	Also known as
English	The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer	scientific article published on 11 December 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063020%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063020%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

6

object named as

Dennis S Chi

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063020%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Richard R Barakat

5

object named as

Richard R Barakat

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063020%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

3

object named as

Yukio Sonoda

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063020%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Nadeem R. Abu-Rustum

2

object named as

Nadeem R Abu-Rustum

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063020%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Eric L Eisenhauer

1

object named as

Eric L Eisenhauer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063020%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Carol Aghajanian

4

object named as

Carol Aghajanian

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063020%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

11 December 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063020%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063020%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

108

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063020%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063020%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

276-281

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063020%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

Epithelial ovarian carcinoma: principles of primary surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

Does debulking surgery improve survival in biologically aggressive ovarian carcinoma?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

Estimating the Relative Risk in Cohort Studies and Clinical Trials of Common Outcomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

A modified poisson regression approach to prospective studies with binary data

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.022

7 January 2021

Identifiers

10.1016/J.YGYNO.2007.10.022

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063020%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063020%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q80155214&oldid=1752934062"